CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for EyeGene Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

EyeGene Inc
No. 1211, 12F, B dong, 401
Yangcheon-ro, Gangseo-gu
Phone: +82 23221687p:+82 23221687 SEOUL, 07528  South Korea Ticker: 185490185490
Business Summary
EyeGene, Inc. is a Korea-based company mainly engaged in the development of therapeutics, diagnostics, and technologies for eye-related diseases. The Company’s products consist of EG-Mirotin, which is a therapeutics of ocular angiogenesis of the diagnostic of early-stage of diabetic retinopathy (DR) and retinopathy of prematurity (ROP); EG-Decorin, a topical ointment for pressure ulcer and diabetic foot ulcer; EG-HPV, a human papillomavirus vaccine; EGS, a scarless wound repair agent, and EG-Vac, a novel vaccine adjuvant for various vaccine preparations.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Seok GeunChoi 57 2/20/2024 2/20/2024
Chief Financial Officer, Director Myeong JaeLee 46 2/20/2024 2/20/2024
Internal Auditor Jong DuChoi 52
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 58 (As of 3/31/2019)
Outstanding Shares: 27,029,784 (As of 1/12/2024)
Shareholders: 27,808
Stock Exchange: KDQ
Fax Number: +82 23024359


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 15, 2024